致《经皮冠状动脉介入治疗后基于短效强效P2Y12抑制剂的双联抗血小板治疗与基于氯吡格雷的双联抗血小板治疗：一项倾向匹配的真实世界研究》 - Suppr | 超能文献

Letter to "Short-Course Potent P2Y12 Inhibitor-Based DAPT Versus Clopidogrel-Based DAPT After PCI: A Propensity-Matched Real-World Study".

作者信息

Zhao Peng, Liang Shanshan

机构信息

Department of Pharmacy, Qingdao Public Health Clinical Center, Qingdao, 266033, Shandong, China.

出版信息

Cardiovasc Drugs Ther. 2025 Aug 23. doi: 10.1007/s10557-025-07762-6.

DOI:10.1007/s10557-025-07762-6

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Letter to "Short-Course Potent P2Y12 Inhibitor-Based DAPT Versus Clopidogrel-Based DAPT After PCI: A Propensity-Matched Real-World Study".致《经皮冠状动脉介入治疗后基于短效强效P2Y12抑制剂的双联抗血小板治疗与基于氯吡格雷的双联抗血小板治疗：一项倾向匹配的真实世界研究》

Cardiovasc Drugs Ther. 2025 Aug 23. doi: 10.1007/s10557-025-07762-6.

2

Short-Course Potent P2Y Inhibitor-Based DAPT Versus Clopidogrel-Based DAPT After PCI: A Propensity-Matched Real-World Study.PCI术后基于短期强效P2Y抑制剂的双联抗血小板治疗与基于氯吡格雷的双联抗血小板治疗：一项倾向评分匹配的真实世界研究

Cardiovasc Drugs Ther. 2025 Jul 26. doi: 10.1007/s10557-025-07750-w.

3

De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.经皮冠状动脉介入治疗后急性冠状动脉综合征患者双联抗血小板治疗的降阶梯治疗：一项系统评价和网状Meta分析

BMJ Evid Based Med. 2024 May 22;29(3):171-186. doi: 10.1136/bmjebm-2023-112476.

4

Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.急性冠状动脉综合征患者药物洗脱支架置入术后的短期双联抗血小板治疗：一项系统评价和网状Meta分析

JAMA Cardiol. 2024 Dec 1;9(12):1094-1105. doi: 10.1001/jamacardio.2024.3216.

5

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor.根据P2Y12抑制剂类型，冠状动脉支架置入术后的P2Y12抑制剂单药治疗

Heart. 2021 Jun 11;107(13):1077-1083. doi: 10.1136/heartjnl-2020-318821.

6

Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.短期 DAPT 与急性冠状动脉综合征患者的 DAPT 降级策略：系统评价和网络荟萃分析。

Circ Cardiovasc Interv. 2023 Sep;16(9):e013242. doi: 10.1161/CIRCINTERVENTIONS.123.013242. Epub 2023 Aug 23.

7

Efficacy and Safety of P2Y monotherapy vs standard DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials.经皮冠状动脉介入治疗患者中 P2Y 单药治疗与标准 DAPT 的疗效和安全性：随机试验的荟萃分析。

Curr Probl Cardiol. 2024 Aug;49(8):102635. doi: 10.1016/j.cpcardiol.2024.102635. Epub 2024 May 13.

8

Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome.吲哚布芬与阿司匹林用于老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后的比较

BMC Cardiovasc Disord. 2025 Jul 7;25(1):495. doi: 10.1186/s12872-025-04843-0.

9

Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.强效 P2Y12 抑制剂与氯吡格雷在急性冠脉综合征后预测抗血小板治疗的依从性：来自 IDEAL-LDL 的观察。

Rev Cardiovasc Med. 2022 Mar 3;23(3):81. doi: 10.31083/j.rcm2303081.

10

Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.急性冠脉综合征患者中从强效 P2Y12 抑制剂的有指导和无指导降级：一项荟萃分析。

Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):492-502. doi: 10.1093/ehjcvp/pvab068.

本文引用的文献

1

Predictors of Five-Year Outcomes in Patients with Acute Coronary Syndromes.急性冠状动脉综合征患者五年预后的预测因素

J Cardiovasc Dev Dis. 2025 Jun 18;12(6):234. doi: 10.3390/jcdd12060234.

2

Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.CYP2C19 基因分型指导急性冠状动脉综合征或经皮冠状动脉介入治疗患者抗血小板治疗的临床实用性。

Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi: 10.1161/ATVBAHA.118.311963.